P&G earnings
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble estimates first quarter earnings of $.72 per share, an increase of 14% versus the prior-year quarter, company announces during the Prudential Back to School Consumer Conference Sept. 9. The marketer of Crest oral care products also expects organic sales growth in Q1 to be in the 4% to 6% range, excluding the estimated impacts of acquisitions and divestitures as well as foreign exchange. The estimates are based in part on "robust" first-quarter initiatives, the firm notes...
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.